FLASH Radiotherapy
Note: This page is educational. FLASH radiotherapy is an investigational radiation-delivery approach, not a routine replacement for conventional radiotherapy.
TL;DR
FLASH radiotherapy (FLASH-RT) delivers ionizing radiation at ultra-high dose rates, commonly defined as at least 40 Gy/s. The core promise is a better therapeutic window: similar tumor control with less normal-tissue injury. Preclinical data are strong enough to justify clinical trials, and the first-in-human proton FAST-01 study showed clinical workflow feasibility in painful extremity bone metastases. As of May 2026, FLASH-RT is still investigational. Sources: [1], [2], [3]
1. What makes it different
Conventional radiotherapy mainly changes:
- total dose
- dose per fraction
- target volume
- beam energy
- anatomic conformation
FLASH adds another variable: dose rate. Instead of delivering radiation over seconds or minutes at conventional dose rates, FLASH attempts to deliver a prescribed dose in a very short time window.
The biological claim is not "more radiation." It is different radiobiology under extreme delivery timing.
2. Why it matters
Radiotherapy is often limited by normal tissue:
- skin
- mucosa
- lung
- bowel
- brain
- bone marrow
- nerves
- pediatric growth and development
If FLASH can preserve tumor control while reducing late toxicity, it could matter most in settings where normal tissue sparing is the bottleneck: reirradiation, pediatrics, central nervous system tumors, thoracic targets, sarcoma, and hypofractionated regimens.
3. Evidence snapshot
| Evidence layer | What it shows | Interpretation |
|---|---|---|
| Preclinical models | Normal tissue sparing with comparable tumor effect in selected models | Strong signal, but mechanism and generalizability remain debated |
| FAST-01 | Proton FLASH feasible for painful extremity bone metastases; adverse events were mild and consistent with conventional palliative RT | Important feasibility milestone, small nonrandomized study |
| FAST-02 | Protocol extends feasibility testing to painful thoracic bone metastases | Still early clinical translation |
| Registry-backed status | Check trial registries before claiming active/recruiting/completed status | Trial stage can change without the paper changing |
Sources: [2], [3], [4] | Routine oncology | Not standard of care | Needs randomized trials, QA, dosimetry, and device validation |
4. Mechanistic hypotheses
Proposed mechanisms include:
- transient oxygen depletion
- differential redox chemistry
- lower normal-tissue inflammatory signaling
- immune and vascular effects
- dose-per-pulse effects
- sparing of stem or progenitor compartments
- altered DNA damage processing kinetics
No single mechanism explains every observation. The safest statement is that FLASH is a delivery-dependent radiobiology phenomenon still being mapped.
5. Engineering bottlenecks
FLASH is hard because the clinical system must control:
- beam current and pulse structure
- field size
- depth dose
- monitor chamber saturation
- absolute dosimetry
- motion management
- treatment planning
- safety interlocks
- independent QA
- machine log reconstruction
The clinical question is not only "does FLASH biology work?" It is also "can a hospital deliver it reproducibly and audit every fraction?"
6. What it is not
FLASH is not:
- a new drug
- a tumor-specific molecular therapy
- automatically safer for every anatomy
- proven for curative cancer treatment
- something available on ordinary radiotherapy machines without validation
It is a promising radiation-delivery paradigm that still needs disease-specific clinical evidence.
7. What technologists can build
- Dose-rate-aware treatment planning that tracks dose, dose rate, dose per pulse, and beam-on time.
- QA dashboards for machine logs, monitor units, beam current, and delivered field geometry.
- Radiobiology data models linking dose-rate parameters with toxicity and response.
- Simulation tools for oxygen, radical chemistry, and tissue response.
- Trial data infrastructure for harmonized toxicity, imaging, and patient-reported outcomes.
8. Brazilian context
FLASH-RT depends on advanced radiotherapy infrastructure, specialized physics teams, and regulatory review. For Brazil, the near-term opportunity is probably research collaboration, data science, medical physics training, and participation in multicenter clinical protocols rather than immediate broad deployment.
See also
References
- Favaudon V, Caplier L, Monceau V, et al. Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice. Sci Transl Med 2014;6:245ra93. PMID 25031268. https://doi.org/10.1126/scitranslmed.3008973
- Mascia AE, Daugherty EC, Zhang Y, et al. Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial. JAMA Oncol 2023;9:62-69. PMID 36273324. https://doi.org/10.1001/jamaoncol.2022.5843
- Daugherty EC, Zhang Y, Xiao Z, et al. FLASH radiotherapy for the treatment of symptomatic bone metastases in the thorax (FAST-02): protocol for a prospective study of a novel radiotherapy approach. Radiat Oncol 2024;19:34. PMID 38475815. https://doi.org/10.1186/s13014-024-02419-4
- ClinicalTrials.gov. Learn About the API. https://clinicaltrials.gov/data-about-studies/learn-about-api